GLAXOSMITHKLINE PHARMACEUTICALS LTD. Q4 FY26 Results

Summary

GSK India announced profitable growth and margin expansion for the fourth quarter and full year ended 31st March 2026. The company reported full year revenue of ₹3,790 crores, a 2% increase, with Profit After Tax (PAT) growing by 10% to ₹1,012 crores and EBITDA margins expanding by 290 basis points to 34%. For the fourth quarter, revenue was ₹989 crores and PAT was ₹275 crores, with EBITDA margins improving by 90 basis points to 35%. This performance was driven by pricing measures, investments in innovative therapies, and disciplined cost management, despite supply chain disruptions impacting topline growth during the year. Management emphasized the strong delivery of the Oncology portfolio as a key inflection point and expressed commitment to investing in high-growth therapy areas for sustainable profitability.

Key Highlights

1. 1

   GlaxoSmithKline Pharmaceuticals Ltd (GSK India) reported full year revenue of ₹3,790 crores for the year ended 31st March 2026, marking a growth of 2%.

2. 2

   Profit After Tax (PAT) for the full year increased by 10% to ₹1,012 crores.

3. 3

   EBITDA margins for FY26 expanded by 290 basis points, reaching 34%.

4. 4

   For the fourth quarter ended 31st March 2026, the Company's revenue stood at ₹989 crores and Profit After Tax (PAT) at ₹275 crores.

5. 5

   Q4 FY26 saw EBITDA margins improve by 90 basis points to 35%.

6. 6

   The Company's Board of Directors recommended a final dividend of ₹57 per equity share for the year ended 31st March 2026.

7. 7

   A key milestone achieved was Jemperli's first-line approval by Indian regulators for primary advanced and recurrent endometrial cancer, significantly expanding the eligible patient population.